[1]Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023 Apr;11(4):354-366.[2]Benjamin J. Solomon,et al.Lorlatinib vs crizotinib in treatment-na¨ıve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.2024 ASCO.Abs#LBA8503.[3]T. Mok, et al. Patterns of Progression with Lorlatinib and insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC.2024 WCLC.Abs#MA06.07.[4]Yi-Long Wu,et,al.First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC）: 5-year outcomes from the CROWN study.2024 ESMO.Abs#1279P.[5]Tao Y, Zhou Y, Tang L, Chen H, Feng Y, Shi Y. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Invest New Drugs. 2022 Aug;40（4）:831-840.[6]Kinetics and Management of Adverse Events Associated with orlatinib after 5 vears of Follow-Up in the CRoWN study.2024 WCLC.Abs#MA06.07.MA06.08. * 此文仅用于向医学人士提供科学信息，不代表本平台观点更多医疗资讯，点击“阅读原文”查看
